Last reviewed · How we verify
MV130
At a glance
| Generic name | MV130 |
|---|---|
| Sponsor | Inmunotek S.L. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD) (PHASE2, PHASE3)
- Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells (PHASE1, PHASE2)
- Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection (PHASE3)
- Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to COVID-19 Infection in Healthcare Personnel (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MV130 CI brief — competitive landscape report
- MV130 updates RSS · CI watch RSS
- Inmunotek S.L. portfolio CI